Actelion has posted a strong set of figures for 2009 and predicted better to come for this year.

Net profit came in at 311.3 million Swiss francs (about $288 millon), a rise of 2% and a good performance given that earnings were hit by one-off charge of $93.7 million after a dispute with Japan's Asahi Kasei over fasudil. Revenues climbed 23% to 1.77 billion francs, the majority of which came from Tracleer (bosentan), for pulmonary arterial hypertension.

Tracleer sales were up 19% on the like, year-earlier period to 1.51 billion francs, helped by a label extension in the USA and the approval of a paediatric formulation in Europe. Of Actelion’s other products, Ventavis (iloprost), an inhaled therapy for the treatment of PAH, leapt 44% to 136.9 million francs, while sales of Zavesca (miglustat), for patients with Gaucher disease for whom enzyme replacement therapy is not a therapeutic option, climbed 38% to 53.1 million francs.

Chief executive Jean-Paul Clozel said that “sales of our products continued to grow in an increasingly competitive environment” and “our clinical pipeline continues to mature, with five compounds in
advanced development stage”. He added that “our marketing and sales infrastructure in all key pharmaceutical markets worldwide, will allow us to generate best value for our existing and future products.”

Regarding the pipeline, Actelion has high hopes for the investigational insomnia drug, almorexant partnered with GlaxoSmithKline, despite safety concerns over data from a two-week Phase III trial presented at the end of last year. The company says longer-term late-stage studies are currently in preparation.

Chief financial officer Andrew Oakley noted that in 2010, revenue growth will be above 10% and earnings growth will be close to 20%.